No annual revenue total was found in CEL-SCI CORPORATION's SEC filings.
Cel-Sci Corporation (CVM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$17.2 million. As of Jun 30, 2026 it held $6.5 million in cash and investments and $7.9 million in total debt.
Revenue
—
Net income (TTM)
$-10.50M
+48.2% vs year-ago TTM
Operating cash flow (TTM)
$-16.75M
+3.0% vs year-ago TTM
Free cash flow (TTM)
$-16.75M
+3.3% vs year-ago TTM
EPS (TTM)
$-1.54
Dividend per share
None
Shares outstanding
8.41M
-88.7% vs prior year
Net cash
$-1.37M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CVM (NYSE)
- Fiscal year ends
- September 30
- Incorporated in
- CO
- Headquarters
- Vienna, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 725363
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Operating income | -$24.8M | -$26.4M | -$31.5M | -$36.1M | -$36.2M |
| Net income | -$25.4M | -$26.9M | -$32.4M | -$36.7M | -$36.4M |
| Diluted EPS | -$6.27 | -$15.31 | — | -$0.87 | -$0.90 |
| Operating cash flow | -$17.1M | -$18.8M | -$22.8M | -$18.2M | -$18.8M |
| Free cash flow | -$17.2M | -$18.9M | -$23.2M | -$18.9M | -$27.8M |
| Total assets | $28.2M | $27.0M | $30.5M | $50.5M | $75.9M |
| Total liabilities | $12.2M | $14.1M | $17.3M | $18.4M | $19.3M |
| Stockholders' equity | $16.0M | $12.9M | $13.2M | $32.2M | $56.5M |
| Cash and investments | $11.0M | $4.7M | $4.1M | $22.7M | $42.2M |
| Total debt | $15.1M | $11.6M | $13.6M | $13.6M | $15.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 2, 2026 | Sep 30, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 16, 2026 | Jun 14, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 14, 2026 | May 11, 2026 |
All 1007 Cel-Sci Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.